4th February 2014
Nuformix is delighted to announce that in partnership with Vectura a significant collaborative research grant has been awarded to support the development of respiratory products utilising pharmaceutical cocrystals. Awarded under the IUK Formulated Products competition, the grant will support collaborative development of new cocrystal-based respiratory therapies over 18 months, from cocrystal discovery through to preclinical development. Nuformix Chief Executive Officer Dr Dan Gooding said: “This is a significant moment for Nuformix. We are very exited to be working with Vectura – a world-leader in respiratory product formulation and development. The use of cocrystal technology in respiratory disease, in particular in inhaled products, is a novel concept and with Vectura as a partner, we couldn’t be better placed to identify and exploit new applications.”